Keep Your Eyes on Stock News: Nevro Corp. (NYSE:NVRO)

Nevro Corp. (NYSE:NVRO) noted trading -1.98% off 52-week high price. On the other end, the stock has been noted 232.95% away from the low price over the last 52-weeks. The stock changed -0.24% to recent value of $137.34. The stock transacted 199610 shares during most recent day however it has an average volume of 456.11K shares. The company has 31.76M of outstanding shares and 30.23M shares were floated in the market.

On Feb. 3, 2020, Nevro Corp. (NYSE:NVRO) a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, declared that the Company will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 25, 2020.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro’s proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Its earnings per share (EPS) expected to touch remained -31.40% for this year while earning per share for the next 5-years is expected to reach at 25.00%. NVRO has a gross margin of 68.60% and an operating margin of -24.30% while its profit margin remained -25.90% for the last 12 months.

According to the most recent quarter its current ratio was 5.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of 7.57% from the mean of 20 days, 15.10% from mean of 50 days SMA and performed 59.51% from mean of 200 days price. Company’s performance for the week was 3.33%, 15.12% for month and YTD performance remained 16.85%.

Christopher Pacheco has worked as financial analyst until his retirement. He is a well-known research director and portfolio manager for more than 5 years. After many years in the market, he dedicated all his time to write articles highlighting different financial problems.

Christopher Pacheco holds a postgraduate degree in Software Engineering from Canada. ‘The stock market is filled with individuals who know the price of everything, but the value of nothing.’ Christopher is a share market expert, being personally invested for over 6 years. He believes the most valuable nugget of wisdom for new investors is a quote from Phillip Fisher. He has been writing his entire life, and while he has made a career of business and finance reporting, he still enjoys writing short stories and poetry.

Address: 25176 10th Street, Greenfield, CA 93927, USA

Email: [email protected]

Zip code: 93927

Contact # 831-385-8150

Leave a Reply

Your email address will not be published. Required fields are marked *